Impacting CV Risk With Diabetes Medications

Introduction/Overview

CVOTs in T2DM

CVOT GLP-1 RA Summary Results: ELIXA, LEADER, SUSTAIN-6

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

DEVOTE: Composite Primary Outcome Results

DEVOTE: Secondary Outcomes -- Hypoglycemia

Hypoglycemia and CV Risk in Patients With T2DM

Primary MACE Outcome CANVAS

CANVAS: CV Results

CANVAS: Renal Outcomes

CANVAS: 2-Fold Increase in Risk of Amputation, Canagliflozin vs Placebo

CANVAS Results: Benefits and Risks

EMPA-REG OUTCOME: Trial Design

EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG Outcome: Results for CV Death

EMPA-REG Outcome and CANVAS: Hospitalization for HF

EMPA-REG Outcome: AEs

Mechanisms of Action and Amputations: Empagliflozin vs Canagliflozin

SGLT2 Inhibitors and Reduced Volume Overload

The "Fuel Hypothesis" as Explanation of Empagliflozin's Cardiorenal Benefits

Other Potential Mechanisms for CV Benefit Associated With Empagliflozin

Practice Patterns Changing Based on CVOT Data

LEADER: Time to First Renal Event

Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)

Summary and Conclusions

Abbreviations

Abbreviations